title: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
abstract: BACKGROUND
  Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.
  
  
  METHODS
  Women aged 15-25 years, with normal cervical cytology, who were HPV-16/18 seronegative and oncogenic HPV DNA-negative (14 types) at screening participated in a double-blind, randomised, placebo-controlled initial study (n=1113; 560 vaccine group vs 553 placebo group) and follow-up study (n=776; 393 vs 383). 27 sites in three countries participated in the follow-up study. Cervical samples were tested every 6 months for HPV DNA. Management of abnormal cytologies was prespecified, and HPV-16/18 antibody titres were assessed. The primary objective was to assess long-term vaccine efficacy in the prevention of incident cervical infection with HPV 16 or HPV 18, or both. We report the analyses up to 6.4 years of this follow-up study and combined with the initial study. For the primary endpoint, the efficacy analysis was done in the according-to-protocol (ATP) cohort; the analysis of cervical intraepithelial neoplasia grade 2 and above (CIN2+) was done in the total vaccinated cohort (TVC). The study is registered with ClinicalTrials.gov, number NCT00120848.
  
  
  RESULTS
  For the combined analysis of the initial and follow-up studies, the ATP efficacy cohort included 465 women in the vaccine group and 454 in the placebo group; the TVC included 560 women in the vaccine group and 553 in the placebo group. Vaccine efficacy against incident infection with HPV 16/18 was 95.3% (95% CI 87.4-98.7) and against 12-month persistent infection was 100% (81.8-100). Vaccine efficacy against CIN2+ was 100% (51.3-100) for lesions associated with HPV-16/18 and 71.9% (20.6-91.9) for lesions independent of HPV DNA. Antibody concentrations by ELISA remained 12-fold or more higher than after natural infection (both antigens). Safety outcomes were similar between groups: during the follow-up study, 30 (8%) participants reported a serious adverse event in the vaccine group versus 37 (10%) in the placebo group. None was judged related or possibly related to vaccination, and no deaths occurred.
  
  
  CONCLUSIONS
  Our findings show excellent long-term efficacy, high and sustained immunogenicity, and favourable safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.
  
  
  BACKGROUND
  GlaxoSmithKline Biologicals (Belgium).
authors: University of Alberta, 1000-8215 112 Street, Edmonton, AB, Canada, T6G 2C8. broman@docromanowski.com
authors: B
authors: B
authors: Romanowski
authors: P Colares
authors: PC
authors: de Borba
authors: P S
authors: PS
authors: Naud
authors: C M
authors: CM
authors: Roteli-Martins
authors: N S
authors: NS
authors: De Carvalho
authors: J C
authors: JC
authors: Teixeira
authors: F
authors: F
authors: Aoki
authors: B
authors: B
authors: Ramjattan
authors: R M
authors: RM
authors: Shier
authors: R
authors: R
authors: Somani
authors: S
authors: S
authors: Barbier
authors: M M
authors: MM
authors: Blatter
authors: C
authors: C
authors: Chambers
authors: D
authors: D
authors: Ferris
authors: S A
authors: SA
authors: Gall
authors: F A
authors: FA
authors: Guerra
authors: D M
authors: DM
authors: Harper
authors: J A
authors: JA
authors: Hedrick
authors: D C
authors: DC
authors: Henry
authors: A P
authors: AP
authors: Korn
authors: R
authors: R
authors: Kroll
authors: A-B
authors: AB
authors: Moscicki
authors: W D
authors: WD
authors: Rosenfeld
authors: B J
authors: BJ
authors: Sullivan
authors: C S
authors: CS
authors: Thoming
authors: S K
authors: SK
authors: Tyring
authors: C M
authors: CM
authors: Wheeler
authors: G
authors: G
authors: Dubin
authors: A
authors: A
authors: Schuind
authors: T
authors: T
authors: Zahaf
authors: Mary
authors: M
authors: Greenacre
authors: An
authors: A
authors: Sgriobhadair
mesh_terms: D000293:Adolescent; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D010919:Placebos; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines; D010919:Placebos